

Eyes on the Cure: Ocular Melanoma Patient and Caregiver Symposium

Melanoma Research Foundation and

Cole Eye Institute, Taussig Cancer Ctr

April 26-27, 2025

Intercontinental Hotel

9801 Carnegie Ave. Cleveland, OH 44106

Friday (4/25)

Time	Session	Location	Blurb
7:30-9:00PM	Informal Meet and	Intercontinental	Join us for an informal
	Greet	Cleveland	meet and greet to kick
			off the weekend!

Saturday (4/26)

Time	Session	Speaker	Blurb
7:00-8:00AM	Check-In & Breakfast	N/A	N/A
8:00-8:15AM	MRF Welcome	Kyleigh LiPira, MBA, MRF CEO	N/A
8:15-8:30AM	Cancer Center (CCF) Welcome	Dr. Arun Singh Professor of Ophthalmology, Editor, Ocular Oncology and Pathology, Director, Dept. of Ophthalmic Oncology, Cleveland Clinic Cole Eye Institute	N/A
8:30-9:15AM	Patient and Caregiver Panel (CCF Patients and others)	Miriam Kadosh, LCSW, MSW Director of Education and Patient Engagement	Hear from our patient panel who will answer relevant questions to their diagnosis, treatment, quality of

		life and survivorship. Come ready with
		questions!
9:15-9:30AM	BREAK	

Room 1

Time	Session	Speaker	Blurb
9:30-9:45AM	Ocular Surveillance - Tumor Control & Vision Loss	Dr. Arun Singh, Professor of Ophthalmology, Editor, Ocular Oncology and Pathology, Director, Dept. of Ophthalmic Oncology, Cleveland Clinic Cole Eye Institute	The five-year local recurrence rate is about 5% with the majority (90%) of the recurrences occurring within the first 5 years (median time to recurrence=18 months). The predominant site of recurrence was at the tumor margin. Recurrent tumors can be managed by repeat brachytherapy, TTT, or enucleation. The risk of vison loss is significant with 50% having 20/200 or worse vision. Prediction models can be used to predict visual loss following brachytherapy. Trials to avoid radiation induced vision loss are underway.
9:45-10:00AM	DNA Testing: Who, When, Why	Meghan DeBenedictis, Licensed, Certified Genetic Counselor, Clinical Professor of Ophthalmology, Director, Genetics Business Development	This session will highlight the differences between somatic and germline genetic testing. It will explore the value DNA testing as it pertains to prognosis for uveal melanoma, and when additional genetic testing may be indicated.

10:00-10:30AM	Systemic Surveillance	Dr. John Suh,	
10:00-10:30AM	- How	Department Chair of	
	- HOW	<u> </u>	
		Radiation Oncology,	
		Cleveland Clinic	
		Taussig Cancer	
40-20-40-4FAM		Institute	
10:30-10:45AM 10:45-11:00AM		Q&A Panel	
	1: B:	BREAK	1
11:00-11:30AM	Liver Directed Therapy	Dr. Isaacs, Associate	Liver directed
		Staff Medical	therapies are
		Oncology Cleveland	performed in
		Clinic, Cleveland	partnership with
		Clinic Taussig Cancer	providers across
		Institute	multiple medical
			specialties. They
			target uveal
			melanoma therapies
			directly to the liver
			and include
			interventional
			radiologists,
			surgeons, radiation
			oncologists and
			medical oncologists.
			We will review several
			of these therapies."
11:30-12:00PM	Tebentafusp in	Dr. Truong	
40.00 40.20DM	Practice	Lucy Kannady MD	This session will
12:00-12:30PM	Immunotherapies	Lucy Kennedy, MD,	This session will
	and Targeted	Medical Oncologist,	review systemic
	Therapies	Cleveland Clinic	therapy options for
		Taussig Cancer	metastatic uveal
		Institute	melanoma beyond
			tebentafusp. We will
			review targeted
			therapy options,
			including darovasertib
			+ crizotinib, which are
			currently in clinical
			trials. We will review
			emerging immune
			therapy strategies in
			addition to new ways
			to incorporate older
			immune therapies
			into current
			management.

Room 1

Time	Session	Speaker	Blurb
111110	00001011	Opeaker	Diaib

2:00-2:30PM	Impact of Funding	Kyleigh LiPira, MBA	Learn about the
2.00-2.50111	Research in OM	CEO Melanoma	impact of the MRF
	11030diciriii Ori	Research Foundation	funded research
2:35-3:05PM	Preventing	Shaheer Khan, DO	Despite successful
2.00-0.00111	Recurrence in Uveal	Griancer Krian, DO	treatment of the
	Melanoma: The Role		primary tumor, the
	of Adjuvant Therapies		risk of metastasis
	- Trajavani merapise		remains a significant
			concern for those
			diagnosed with uveal
			melanoma. In this
			session, we'll explore
			advancements in
			adjuvant therapies,
			including prior and
			upcoming clinical
			trials as well as the
			rationale for
			immunotherapy and
			targeted approaches.
3:10-3:40PM	Financial Navigation	Jill Harmon, RCM	This presentation
		Financial Counseling	helps patients
			navigate healthcare
			finances, especially
			those with out-of-
			network (OON)
			insurance. It's
			important to
			understand the
			difference between
			in-network and OON
			providers, as OON
			care usually costs more. Patients should
			verify their insurance
			coverage early and
			ask about
			preauthorization
			requirements. Cost
			transparency is key,
			so patients should
			request clear
			estimates for
			consultations,
			imaging, and
			surgeries. For OON
			care, gap exceptions
			may reduce costs. If

			facing high out-of- pocket expenses, payment plans, or financing options can help. Comprehensive medical necessity documentation improves the chances of insurance approval. By verifying coverage, requesting estimates, and exploring payment options, patients can better manage healthcare
3:45-4:15PM	Mental Health and Scanxiety	Carly Temple, MSSA, LISW-S, Social Worker, Cleveland Clinic Taussig Cancer Institute	costs. Join oncology social worker, Carly Temple, LISW-S, as she talks about supporting your wellbeing during cancer care and beyond. Explore ways to cope with scanxiety, discover how mindfulness can be an effective tool to help manage distress, and learn ways to identify and address mental health needs, whether you're the patient or the care

Room 2

Time	Session	Speaker	Blurb
9:30-10:30AM	Art Therapy Session	Lisa Shea, LPAT, ATR-BC	Please join us for, "What Feeds Your Soul?" Participants will be able to create a small unique clay medallion symbolizing
			what people, places

			or things nourish their
9:30-10:30AM	Art Therapy Session	Lisa Shea, LPAT, ATR-BC	soul.
10:30-11:00AM		BREAK	
2:00-2:30PM	An Introduction to Artificial Eyes: Excellence That Goes Unnoticed	Angela Reinhardt, B.CO., B.A.D.O.	What to expect after eye enucleation, the process of making an ocular prosthetic, and restoring your confidence.
2:35-3:05PM	Low Vision Adjustments and Resources	Alicia Howerton, Cleveland Sight Center, Elisha Beard, Cleveland Sight Center	Living life as a person who's blind is more than a process, but it has to start there! An emotional, physical and familial process of which I know firsthand. Self-talk is key, but you can say words from a positive or negative perspective. I've found that intentionality in my thinking has helped me grasp opportunities for a life I didn't think would have been possible twenty plus years ago. You'll hear some of my story and the life adjustments I made as I was losing my vision, but knowing and having the resources available sooner would have helped me greatly and

			you'll hear more about that during the talk.
3:10-3:40PM	Empowered Care: Navigating the Journey of Supporting a Loved One with Cancer	The Gathering Place	Join us for a sacred space just for caregivers!
3:45-4:15PM	Ink & Intentions	Linds Brown, CDTI, CRCST, CFER, CCSVP	Not a journaler? Perfect! This session is designed for those who don't consider themselves writers but still want to reflect, reset, and make the most of their time. Through thoughtful prompts and personal insights, you'll leave with a renewed sense of clarity and motivation to make every moment count and discover how journaling can be a powerful tool—even if you've never picked up a pen for self- reflection before.
4:15-4:30PM	BREAK		
4:30-5:45PM	Support group breakout by diagnosis type	Carly Temple MSSA, LISW-S, Cleveland Clinic Taussig Cancer Institute, Stacie Cindea, Miriam Kadosh, Kyleigh LiPira	Join other attendees for breakout sessions by diagnosis type: primary, metastatic, caregiver, lost a loved one
6:00PM	DINNER – Community Building Activities		

Sunday (4/27)

Time	Session	Speaker	Blurb
8:00-9:00AM	BREAKFAST		During breakfast, we will honor those whom we have lost from OM

0.00.0.00414	I be a state of the state of th	D., A., 0: 4	AACAL Introduction
9:00-9:30AM	Uveal Melanoma: Era of Ocular Trials	Dr. Arun Singh, Professor of Ophthalmology, Editor, Ocular Oncology and Pathology, Director, Dept. of Ophthalmic Oncology, Cleveland Clinic Cole Eye Institute	With high local control rates (95%), visually debilitating sequelae have been accepted by the treating oncologist and the patients alike. To avoid radiation retinopathy (RR) altogether, alternatives to radiation therapy are being sought. Currently, several promising treatments are being investigated in clinical trials, including a light-activated therapy that can selectively destroy the cell membrane of malignant cells, the use of novel pharmaceuticals to prevent and treat the effects of RR, and an oral drug that blocks a critical step in the molecular pathogenesis of uveal melanoma.
9:30-10:00AM	Uveal Melanoma: Am I Cured Yet?	Dr. Arun Singh, Professor of Ophthalmology, Editor, Ocular Oncology and Pathology, Director, Dept. of Ophthalmic Oncology, Cleveland Clinic Cole Eye Institute	Uveal melanoma patients reach normal life expectancy about 25 years after ocular therapy. A very long time to cure suggests that the statistical cure is unlikely to be related to ocular therapy. Conditional survival estimates improve with time since ocular therapy. Conditional survival analysis can provide dynamic and specific

			guidance for
			counselling patients.
10:00-11:00AM	Under the	Jennifer A Brainard,	
	Microscope:	MD	
	Pathology Diagnosis		
	of Ocular Melanoma		
11:00-11:30AM	Q&A Panel		
11:30AM	LUNCH TO GO		
1:40PM	BASEBALL GAME		